Targeting DKK1 has also been used as a potential treatment for different tumor types, including breast cancer [31, 32], non-small cell lung cancer (NSCLC) [33, 34], gastric cancer [35, 36], colorectal cancer [37, 38], and pancreatic cancer [39–41]. This evidence concerns the gene DKK1 and familial pancreatic carcinoma.